Invesco Ltd. 89bio, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in 89bio, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 32,343 shares of ETNB stock, worth $254,215. This represents 0.0% of its overall portfolio holdings.

Number of Shares

32,343

Previous 33,341 2.99%

Holding current value

$254,215

Previous $267,000 10.49%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$7.36 - $9.66 $7,345 - $9,640	-998 Reduced 2.99%	32,343 $239,000
Q2 2024 Aug 13, 2024	SELL	$7.31 - $10.9 $11,410 - $17,014	-1,561 Reduced 4.47%	33,341 $267,000
Q1 2024 May 14, 2024	SELL	$8.13 - $13.77 $539,149 - $913,171	-66,316 Reduced 65.52%	34,902 $406,000
Q4 2023 Feb 12, 2024	BUY	$6.66 - $16.03 $44,315 - $106,663	6,654 Added 7.04%	101,218 $1.13 Million
Q3 2023 Nov 13, 2023	SELL	$15.06 - $19.41 $9.86 Million - $12.7 Million	-654,653 Reduced 87.38%	94,564 $1.46 Million
Q2 2023 Aug 11, 2023	BUY	$14.15 - $22.03 $9.9 Million - $15.4 Million	699,301 Added 1400.96%	749,217 $14.2 Million
Q1 2023 May 12, 2023	SELL	$10.48 - $16.94 $66,139 - $106,908	-6,311 Reduced 11.22%	49,916 $760,000
Q4 2022 Feb 13, 2023	SELL	$5.52 - $12.73 $302,722 - $698,125	-54,841 Reduced 49.38%	56,227 $715,000
Q3 2022 Nov 14, 2022	SELL	$3.02 - $7.0 $37,109 - $86,016	-12,288 Reduced 9.96%	111,068 $643,000
Q2 2022 Aug 15, 2022	BUY	$2.09 - $4.02 $257,814 - $495,891	123,356 New	123,356 $397,000
Q2 2021 Aug 17, 2021	SELL	$17.42 - $28.0 $580,068 - $932,372	-33,299 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$20.22 - $26.73 $43,978 - $58,137	2,175 Added 6.99%	33,299 $789,000
Q4 2020 Feb 16, 2021	BUY	$23.16 - $28.08 $720,831 - $873,961	31,124 New	31,124 $759,000

Others Institutions Holding ETNB

# of Institutions

158

Shares Held

108M

Call Options Held

73.6K

Put Options Held

1.19M

View Full List

About 89bio, Inc.

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $365M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

More about ETNB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account